The
global Melanoma Therapeutics Market is expected to reach USD
12.4 billion by 2025, according to a new report by Grand View Research, Inc.
Increasing incidence of chronic diseases such as melanoma, skin cancer, and
skin allergies is an important driver of the market.
According
to CDC, over 71,943 people were affected by melanoma in 2013. The American
Cancer Society estimates that this number will go up to 87,100 in 2017, thus
highlighting the need for melanoma drugs over the forecast period.
Increasing
number of FDA approvals and introduction of novel therapeutics with enhanced
efficacy are also anticipated to present growth opportunities. Within a period
of 6 years, i.e., from 2011 to 2016, around eight biologics have been approved
for the treatment of this disease, which include Opdivo, Yervoy, Cotellic,
Zelboraf, Keytruda, Mekinist, Tafinlar, and Imlygic.
Companies
are undertaking various R&D activities to find new indications for existing
products and development of innovative molecules. For instance, in September
2014, the U.S. FDA approved patented drug Keytruda (Merck & Co., Inc.) to
treat metastatic melanoma, thereby extending the therapeutic application of its
product. This drug was initially approved for treatment of non-small cell lung
cancer.
Furthermore,
many pharmaceutical companies in the U.S., Europe, and Asia Pacific are
focusing on development of new biologics. For instance, in March 2017, Daiichi
Sankyo Company, Limited announced a collaborative drug discovery project—Take a
New challenge for Drug discovery (TaNeDS)—to facilitate new drug development
through collaborations. Moreover, it entered into a strategic research
collaboration with AgonOX, Inc. to develop new immunotherapy drugs for the
immuno-oncology segment. Approval of novel products over the forecast period is
anticipated to boost market growth.
To request a sample copy or view summary of this report,
click the link below:
http://www.grandviewresearch.com/industry-analysis/melanoma-therapeutics-market
http://www.grandviewresearch.com/industry-analysis/melanoma-therapeutics-market
Further Key Findings From the Study Suggest:
- Targeted
therapy segment is expected to show lucrative growth owing to benefits
such as low adverse effects and higher efficiency
- Branded
drugs held a dominant share of the industry because of patent exclusivity
- Biologics,
such as Opdivo and Cotellic, are expected to exhibit lucrative growth over
the forecast period owing to increase adoption and advantages such
improved therapeutic effects
- The patent
for Yervoy will expire in 2022 in the U.S. and in 2020 in Europe. This is
expected to provide growth opportunities for new market entrants
- Asia Pacific
is expected to exhibit lucrative CAGR over the forecast period
- Key market
players are increasing R&D efforts for discovery and development of
novel drugs for the treatment of melanoma
Grand
View Research has segmented the melanoma therapeutics market on the basis of
therapy, drugs, and region:
Melanoma Therapeutics Therapy Outlook (Revenue, USD
Million, 2014 - 2025)
- Chemotherapy
- Immunotherapy
- Targeted
Therapy
- Radiation Therapy
Melanoma Therapeutics Drugs Outlook (Revenue, USD
Million, 2014 - 2025)
- Opdivo
- Yervoy
- Mekinist+Tafinlar
- Keytruda
- Cotellic
- Zelboraf
- Imlygic
- Generics
Melanoma Therapeutics Regional Outlook (Revenue, USD
Million, 2014 - 2025)
- North
America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia Pacific
- Japan
- China
- India
- Latin
America
- Brazil
- Mexico
- MEA
- South Africa
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, the company offers market intelligence
studies ensuring relevant and fact-based research across a range of industries
including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
No comments:
Post a Comment